Back to 
Balyasny Asset Management L.P.
Balyasny Asset Management L.P.
CHRS
13 quarters
Position history for Balyasny Asset Management L.P.'s holdings in Coherus Oncology, Inc.
No. Balyasny Asset Management exited its CHRS (Coherus Oncology) position in Q1 2024. Its Q4 2023 13F listed 62,451 shares worth $207,962. Balyasny Asset Management already held CHRS in its Q4 2018 13F, the earliest on record, and held it in 10 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$824,000
Total Shares Change
-91,101
Quarter-by-Quarter History
Other major holders of CHRS: Temasek Holdings (Private) Ltd, Wellington Management Group LLP